Preclinical efficacy and toxicity studies of a highly specific chimeric anti‐CD47 antibody
Cluster of differentiation 47 (CD47) is a widely expressed self‐protection transmembrane protein that functions as a critical negative regulator to induce macrophage‐mediated phagocytosis. Overexpression of CD47 enables cancer cells to escape immune surveillance and destruction by phagocytes both in...
Main Authors: | Zhiqiang Xu, Jing Gao, Jingyun Yao, Teddy Yang, Dongxu Wang, Chaohui Dai, Yu Ding |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | FEBS Open Bio |
Subjects: | |
Online Access: | https://doi.org/10.1002/2211-5463.13084 |
Similar Items
-
CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
by: Peter E. van Bommel, et al.
Published: (2018-02-01) -
Antibody:CD47 ratio regulates macrophage phagocytosis through competitive receptor phosphorylation
by: Emily C. Suter, et al.
Published: (2021-08-01) -
Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation
by: Zhiqiang Li, et al.
Published: (2021-08-01) -
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
by: Wenting Zhang, et al.
Published: (2020-01-01) -
Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
by: Lu Q, et al.
Published: (2020-09-01)